Skip to content

Safety and efficacy evaluation of endoscopic retrograde cholangiopancreatography and endoscopic ultrasound-guided lauromacrogol ablation for intraductal papillary mucinous neoplasm communication with the main pancreatic duct: A single-center, prospective cohort study

Safety and efficacy evaluation of endoscopic retrograde cholangiopancreatography and endoscopic ultrasound-guided lauromacrogol ablation for intraductal papillary mucinous neoplasm communication with the main pancreatic duct: A single-center, prospective cohort study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600129078
Enrollment
Unknown
Registered
2026-07-30
Start date
2026-04-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intraductal papillary neoplasms

Interventions

Sponsors

Chinese PLA General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Patients initially diagnosed with IPMN or PCN of undetermined nature by imaging at the First Medical Center of the Chinese People's Liberation Army (PLA) General Hospital from April 1, 2026, to March 1, 2027. 2.Aged 18 to 85 years.

Exclusion criteria

Exclusion criteria: 1. Patients requiring repeat hospital admission for EUS-guided ablation during the study period. 2. Patients with main-duct IPMN (MD-IPMN). 3. Number of cystic lesions >=6. 4. Inability to rule out malignancy (presence of mural nodules, solid components, eggshell calcification of the cyst wall, cystic fluid cytology suggestive of malignancy or high-grade dysplasia, main pancreatic duct dilation >10 mm, or associated symptoms). 5. History of pancreatitis or evidence of pancreatic necrosis. 6. Presence of contraindications to EUS, ERCP, anesthesia, or the use of lauromacrogol. 7.Patients with other comorbid conditions deemed by the investigator to be unsuitable for enrollment, or with a predicted short life expectancy. 8. Pregnant or breastfeeding women. 9. Coagulation dysfunction. 10. Patients who are unwilling or unable to provide informed consent.

Design outcomes

Primary

MeasureTime frame
The rates of complications after EUS-guided ablation (Safety);

Secondary

MeasureTime frame
The response rate of IPMN (including complete response and partial response);The incidence of diabetes mellite;The incidence of pancreatic cancer;The incidence of symptoms such as abdominal pain and jaundice ;Incidence and severity of complications throughout the entire treatment process;The success rate of ERCP cannulation ;The success rate of stent placement ;Length of hospital stay and costs;Adverse event;Recurrent pancreatic intraductal papillary mucinous tumor (IPMN);

Countries

China

Contacts

Public ContactChai Ningli

Chinese PLA General Hospital

chainingli@vip.163.com+86 10 6693 7485

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Aug 10, 2026